Findings

What do systematic reviews say?

8 questions · 8 findings · 1 reviews · Haematology

No studies found 1 · 12.5%GRADE not reported 1 · 12.5%Very low 2 · 25%Low 2 · 25%Moderate 2 · 25%High 0 · 0%

Overall survival · Adult patients with myelodysplastic syndromes and thrombocytopenia

1 finding from 1 review

Thrombopoietin mimetics for patients with myelodysplastic syndromes 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 282 participants
GRADE not reported

Mortality during study · Adult patients with myelodysplastic syndromes and thrombocytopenia

Thrombopoietin mimetics showed no clear difference in mortality during study compared with placebo (low certainty).

1 finding from 1 review

Thrombopoietin mimetics for patients with myelodysplastic syndromes 2017 · Cochrane Headline outcomes only
RR 0.97 [0.73, 1.27]
6 studies · 746 participants
Low

Transformation to AML · Adult patients with myelodysplastic syndromes and thrombocytopenia

It is very uncertain whether thrombopoietin mimetics changes transformation to AML compared with placebo (very low certainty).

1 finding from 1 review

Thrombopoietin mimetics for patients with myelodysplastic syndromes 2017 · Cochrane Headline outcomes only
RR 1.02 [0.59, 1.77]
5 studies · 372 participants
Very low

Incidence of bleeding events · Adult patients with myelodysplastic syndromes and thrombocytopenia

Thrombopoietin mimetics probably leads to lower incidence of bleeding events compared with placebo (moderate certainty).

1 finding from 1 review

Thrombopoietin mimetics for patients with myelodysplastic syndromes 2017 · Cochrane Headline outcomes only
RR 0.92 [0.86, 0.98]
5 studies · 390 participants
Moderate

Blood transfusion requirements · Adult patients with myelodysplastic syndromes and thrombocytopenia

Thrombopoietin mimetics showed no clear difference in transfusion requirement compared with placebo (low certainty).

1 finding from 1 review

Thrombopoietin mimetics for patients with myelodysplastic syndromes 2017 · Cochrane Headline outcomes only
RR 0.83 [0.66, 1.05]
4 studies · 358 participants
Low

Health‐related quality of life · Adult patients with myelodysplastic syndromes and thrombocytopenia

The review found no eligible studies for this question.

1 finding from 1 review

Thrombopoietin mimetics for patients with myelodysplastic syndromes 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

All adverse events · Adult patients with myelodysplastic syndromes and thrombocytopenia

Thrombopoietin mimetics showed no clear difference in all adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Thrombopoietin mimetics for patients with myelodysplastic syndromes 2017 · Cochrane Headline outcomes only
RR 1.01 [0.96, 1.07]
5 studies · 390 participants
Moderate

Serious adverse events · Adult patients with myelodysplastic syndromes and thrombocytopenia

It is very uncertain whether thrombopoietin mimetics changes serious adverse events compared with placebo (very low certainty).

1 finding from 1 review

Thrombopoietin mimetics for patients with myelodysplastic syndromes 2017 · Cochrane Headline outcomes only
RR 0.89 [0.54, 1.46]
4 studies · 356 participants
Very low